Independent
Tenure on this board
2.2 yrs
Also a director at
Precipio Inc (PRPO)Bolt Biotherapeutics Inc (BOLT)
3 nominees · 3 ballot items.
Elect three Class II directors; Ratify Ernst & Young LLP as independent auditor; Advisory approval of named executive officer compensation.
Elect Kathleen LaPorte, Jodie Morrison, and Arthur Tzianabos, Ph.D. as Class II directors to serve three-year terms until 2029.
Ratify the appointment of Ernst & Young LLP as Q32 Bio’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
This management proposal requests that stockholders ratify the audit committee’s selection of Ernst & Young LLP (EY) as the company’s independent registered public accounting firm for the 2026 fiscal year. Management frames the vote as a corporate governance best practice rather than a legal requirement and indicates that the audit committee retains discretion to change auditors regardless of the shareholder vote. Background context includes EY’s service since March 2024 and pre-merger service to Legacy Q32 since 2020; the company disclosed EY fees for audit, audit-related and tax services for 2024 and 2025, and described an audit committee pre-approval policy for audit and non-audit services. The Board recommends a vote FOR, noting that ratification provides shareholder input on the selection — and signals approval of EY’s independence and performance — while also preserving the committee’s ability to act if concerns arise. Material considerations for analysts include the total fees paid to EY (modest relative to company size), the existence of non-audit fees (audit-related and tax services), and the board’s explicit contingency that it may replace EY irrespective of ratification, which together inform assessments of auditor independence and potential audit quality issues.
Non-binding, advisory approval of compensation paid to the company’s named executive officers as disclosed in the proxy statement.
This management proposal seeks a non-binding advisory endorsement (Say-on-Pay) of the company’s executive compensation program as disclosed in the proxy. Management argues that the compensation programs are designed to attract and retain qualified executives, align executives’ interests with stockholders through a mix of base salary, annual performance-based cash bonuses, and long-term equity incentives, and that the company’s compensation committee used an independent consultant (Aon) to benchmark pay. The Board recommends a vote FOR. Analysts should weigh factors including recent option repricing, the size and structure of equity awards and cash incentives, change-in-control protections, and the link between pay and performance metrics disclosed in the Pay Versus Performance tables. Because the vote is advisory, it carries no binding effect, but a negative outcome would likely prompt management to revisit compensation practices given the company’s stated intent to consider shareholder feedback.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLCActivist | 13.3% | 2,252,987 | $14M |
| 2 | Atlas Venture Life Science Advisors, LLC | 12.3% | 2,092,106 | $13M |
| 3 | Opaleye Management Inc. | 7.4% | 1,256,228 | $8M |
| 4 | Carlyle Group Inc. | 6.5% | 1,102,741 | $7M |
| 5 | ARCH Venture Management, LLC | 1.9% | 320,482 | $2M |
| 6 | ACORN CAPITAL ADVISORS, LLC | 1.9% | 315,052 | $2M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 1.8% | 306,401 | $2M |
| 8 | MACKENZIE FINANCIAL CORP | 1.5% | 246,304 | $2M |
| 9 | Sanofi | 1.4% | 244,083 | $2M |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 1.2% | 206,915 | $1M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.